Access and Evidence
Real World Evidence: Supporting Decision-Making
How can pharma use observational data to support discovery, research & early development?
More Access and Evidence Articles
Access and Evidence
Biosimilars: Value or Innovation, or both?
The biosimilar market is picking up pace and eyeforpharma's head analyst, Magnus Franzen, met with two companies that are seeing a key role for their future businesses in biosimilars. They discussed how biosimilars are both value and innovation, as well as a definite part of the future of pharma.
Access and Evidence
The Art of Collaboration
Mundipharma has set great store by getting customers involved early in the development process, and on bringing in people from all over pharma to offer their input on potential solutions.
Access and Evidence
Early access: Taking stock of the options
But just when is access really early, and what are the options for companies to consider in 2015?
Access and Evidence
Real World Evidence: Maximize Benefits To Healthcare
With a staggering cost of drug development estimated at US$2.6 billion and a high failure rate of new compounds, pharma is under pressure to develop solutions that improve the R&D hit rate. Real World Evidence combined with digital healthcare might be what the industry is looking for.
Access and Evidence
The Price of Global Health: A guide to access and pricing
Ed Schoonveld, author of The Price of Global Health, argues that a ‘perfect storm’ is approaching as disease burdens rise and drug budgets fall. But pharma can navigate this by thinking carefully about its value proposition, understanding the decision makers – and telling better stories.
Access and Evidence
Market Access: A cross-functional priority
eyeforpharma spoke to Jan Weinreich, Director of Market Access at Roche in Italy, ahead of his presentation at Market Access & Pricing Excellence 2015, about his perspective on the future of market access in Europe and the need for the industry to adapt to changes to national healthcare systems.
Access and Evidence
Making tenders work globally: The Pfizer approach
Tenders are an everyday part of the market access and pricing process for pharmaceutical and biotech companies. Suzanne Elvidge spoke to Nico Bacharidis, Global Tender & Contracting Lead for Established Products at Pfizer, about Pfizer's approach to global tender management.
Access and Evidence
Market Access in Europe: homogenizing or fragmenting further?
Richard Bergström, Director General, EFPIA argued passionately in favor of the homogenization of European HTA bodies and regulation, during a recent interview with Paul Simms, Chairman, eyeforpharma.
Access and Evidence
Year in Review 2014: Market Access
Market access is a labyrinth pharma must navigate to bring their products to patients. Throughout 2014, we followed the introduction of early access schemes, gathered tips on preparing the perfect value proposition, and attempted to answer the all important question: what is value in healthcare?